NCT03524170: Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT03524170
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 1 line of endocrine therapy
Exclusions: Patients with active central nervous system (CNS) metastases with significant neurological compromise or symptoms- see trial for details; Patients who have received more than 5 previous lines of chemotherapy
https://ClinicalTrials.gov/show/NCT03524170

Comments are closed.

Up ↑